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Abstract
The prevalence of orofacial clefts (OFCs) is nearly 10.2 per 10,000 births in the United States 
and 9.9 per 10,000 births worldwide. OFCs occur as a result of a break (nonfusion) of oro-
facial structures during development. This can occur due to a variety of reasons;prenatal 
exposure to many drugs and environmental factors as well as genetic factors which are 
implicated in the development of OFCs. While approximately 15 types of clefts have been 
identified, there are at least four distinct classifications of OFCs. These include complete 
cleft palate with cleft lip; cleft of the anterior palate, which may/may not involve cleft lip; 
cleft of the posterior palate; and submucosal cleft. A number of candidate genes have been 
identified, including transforming growth factor beta (TGFβ) and homeobox genes (e.g., 
MSX1), among many others. What follows is a review of mouse models currently used in 
research and the classification of their overall contribution to known OFCs.
Keywords: orofacial, cleft lip, cleft palate, genomic, genetics, TGFβ, MSX1, knockout 
mice, craniofacial, molecular, palatogenesis
1. Introduction
The focus of this chapter is to review a comprehensive list of the genes with known involve-
ment in generating cleft lip with (or without) cleft palate (CL/P) or cleft palate (CP) in mice. 
Additionally, the associated knockout (KO) and conditional knockout (cKO) models are dis-
cussed. Most of the research models currently in use focus on complete CP, and thus not 
as much is known of the other CP phenotypes. In particular, identifying specific risk genes 
for CL/P is made simpler when genomic sequencing is done, and clefting associated with 
syndromes (syndromic) has identified single genetic loci that are involved with abnormali-
ties in palatogenesis. Current mouse models involve a somewhat surprisingly vast array of 
genes, however, including Wnt, Msx1/2, Tbx, Pax9, Irf6, Tgfb, and Fgf. Further elucidation and 
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 categorization of these gene families and their associated defects—whether syndromic or 
non-syndromic—can aid us in further clarifying the molecular mechanisms underlying oro-
facial clefting and potentially lead us to targeted, more efficient treatments.
We currently utilize four distinct classifications for OFCs: complete cleft palate with cleft lip; cleft 
of the anterior palate, which may/may not involve cleft lip; cleft of the posterior palate; and sub-
mucosal cleft. Subdivided among these four classifications of OFCs are six categories of develop-
mental defects that have been shown to result in cleft palate in KO or cKO mice. The numerous 
variants of CL/P can generally be found to fit within one of the following categories: [1]
1. Palatal shelf formation failure
2. Abnormal fusion of palatal shelves
3. Delayed/failed elevation of the palatal shelves
4. Failure of palatal shelf development post-elevation
5. Persistence of medial-edge epithelial cells
6. Secondary defect
Each of the known KO/cKO mice mentioned is bred such that the gene missing is one already 
known to play a role in the development of CL/P. Implicit within these categories are the KO 
genes known to lead to each particular type of defect, each of which will be outlined as we 
move through this chapter.
As we look into the future, OFCs need to be classified with more definitive nomenclature. 
Currently, we use arbitrary terms to define very broadly into which category these congeni-
tal malformations fall, i.e., syndromic versus non-syndromic. As studies are broadened to 
include a wider array of genetic variants and their regulatory regions, more risk genes for 
CL/P and CP will surely be identified. As a result, more specific phenotypic classifications will 
emerge as well. The etiology of OFCs is complex, and the presentation is wide ranging; it is 
important that we continue to use precise genetic mouse models in order to carefully define 
a given phenotype before reclassifying human cases. The models mentioned in this chapter 
and those developed in the future are critical to a more sophisticated understanding of OFC 
anomalies and etiologic variants. Their development and utilization will ideally lead to a 
greater breadth and depth of treatment intervention options for patients.
2. Current mouse models utilized for elucidation of molecular 
mechanisms involved in orofacial clefting
As alluded to previously, a great breadth of genes plays critical roles in palatogenesis. Upon 
further analysis, a subset of gene families and signaling pathways have emerged as containing 
the most significant molecules related to normal development of the palate. Of note are the 
following: transforming growth factor beta (TGFβ), hedgehog, Wnt, fibroblast growth factor 
(FGF), and the mitogen-activated protein kinase (MAPK) signaling pathway. Each signaling 
pathway has an expansive list of genes with known involvement in palatogenesis (Table 1).
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Gene Syndromic/non-syndromic Orofacial phenotype
Acvr1/Alk2 Submucosal cleft/fibrodysplasia ossificans  
progressiva
Und
Acvr2a Und Und
Akap8/Akap95 Und Und
Alx1 Frontonasal dysplasia 3 CL/P
Alx3 Frontonasal dysplasia 1 CL/P
Alx4 Frontonasal dysplasia 2, parietal foramina 2,  
craniosynostosis 5
Cleft alae nasi
Anp32b Und Und
Apaf1 Und Und
Arid5 Und Und
Asxl1 Bohring-Opitz syndrome; myelodysplastic  
syndrome, somatic
CL/P
B9d1 Meckel syndrome 9 Und
Barx1 Und Und
Bmp4 Microphthalmia, syndromic 6 CL/P
Bmp7 Und Und
Bmpr1a/Alk3 Juvenile polyposis syndrome CP
Cask FG syndrome 4, mental retardation, and microcephaly  
with pontine and cerebellar hypoplasia
CL/P
Cdc42 Und CL/P
Cdkn1c/p57kip2 Beckwith-Wiedemann syndrome, IMAGe syndrome CL/P
Ceacam1 Und Und
Chd7 CHARGE syndrome CL/P
Chrd Und CL
Chuk/Ikk1/Tcf16 Cocoon syndrome Und
Cited2 Atrial septal defect 8, ventricular septal defect 2 Und
Col2a1 Achondrogenesis, type II; Stickler syndrome, type I;  
Kniest dysplasia
CL/P
Crebbp/Cbp Rubinstein-Taybi syndrome Und
Crk Und Und
Ctgf Und Und
Ctnnb1 Mental retardation, autosomal dominant 19 Und
Cyp26B1 Craniosynostosis with radiohumeral fusions and other  
skeletal and craniofacial anomalies
Und
Cyp51 Und Und
Dhcr7 Smith-Lemli-Opitz syndrome CL/P
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Gene Syndromic/non-syndromic Orofacial phenotype
Dhrs3 Und Und
Dicer1 Rhabdomyosarcoma, embryonal, 2; goiter,  
multinodular 1; pleuropulmonary blastoma
Und
Dlg1/Dlgh/Sap97 Und Und
Dlx1 Und Und
Dlx2 Und Und
Dlx5 Split-hand/foot malformation 1 with sensorineural  
hearing loss
CL/P
Dph1/Ovca1 Und Und
Edn1 Auriculocondylar syndrome 3 CL/P
Efna5 Und Und
Efnb1 Craniofrontonasal dysplasia CL/P
Efnb2 Und Und
Egfr Und Und
Eya1 Branchiootic syndrome 1; branchiootorenal syndrome 1,  
with or without cataracts; anterior segment anomalies  
with or without cataract
CL/P
Fgf10 Aplasia of lachrymal and salivary glands Und
Fgf18 Und Und
Fgf9 Und Und
Fgfr1 Non-syndromic cleft lip/palate, Hartsfield syndrome, 
hypogonadotropic hypogonadism 2, Pfeiffer syndrome
CL/P
Fgfr2 Apert Syndrome CL/P
Foxc2/Mfh1 Lymphedema-distichiasis syndrome CL/P
Foxd3 Und Und
Foxe1/Titf2/Fkhl15 Bamforth-Lazarus syndrome CL/P
Foxf2 Und Und
Fst Und Und
Fuz Neural tube defects Und
Fzd2 Und Und
Gab1 Und Und
Gabrb3 Epilepsy, childhood absence, susceptibility to, 5 CL/P
Gad/Gad67 Cerebral palsy, spastic quadriplegic, 1 CL/P
Gbr2 Und Und
Gbx2 Und Und
Gdf11/Bmp11 Und Und
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Gene Syndromic/non-syndromic Orofacial phenotype
Glce Und Und
Glg1 Und Und
Gli2 Culler-Jones syndrome, holoprosencephaly-9 CL/P
Gli3 Greig cephalopolysyndactyly CL/P
Gpr124 Und Und
Grb2 Und Und
Gsc Short stature, auditory canal atresia, mandibular  
hypoplasia, skeletal abnormalities
Und
Gsk3b Und Und
Hand2/dHand Und Und
Hic1 Und Und
Hoxa2 Microtia with or without hearing impairment Und
Hs2st1 Und Und
Hspb11/Ift25 Und Und
Hspg2 Dyssegmental dysplasia, Schwartz-Jampel  
syndrome, type 1
Und
Ilk Und Und
Impad1/Jaws Chondrodysplasia with joint  
dislocations, GRAPP type
CL/P
Inhba Und Und
Inpp5e Mental retardation, truncal obesity, retinal  
dystrophy, and micropenis
Und
Irf6 Van der Woude syndrome, orofacial cleft 6, popliteal  
pterygium syndrome 1
CL/P
Itgb1 Und Und
Itgb8 Und Und
Jag1 Alagille syndrome Und
Jag2 Und Und
Jmjd6/Ptdsr Und Und
Kat6a/Moz/Myst3 Und Und
Kcnj2 Andersen syndrome, atrial fibrillation,  
familial, 9; short QT syndrome 3
CL/P
Kif3a Und Und
Lhx7 Und Und
Lhx8 Und Und
Lrp6 Und Und
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Gene Syndromic/non-syndromic Orofacial phenotype
Luzp1 Und Und
Map3k7/Tak1 Und Und
Mef2c Chromosome 5q14.3 deletion syndrome, mental  
retardation, stereotypic movements, epilepsy,  
and/or cerebral malformations
Und
Meox2 Und Und
Mn1 Meningioma Und
Mnt Und Und
Msx1 Ectodermal dysplasia 3,  
Witkop-type Orofacial cleft 5
CL/P
Msx2 Craniosynostosis, type 2; parietal foramina 1, 
 parietal foramina with cleidocranial dysplasia
CL/P
Nabp2/Obfc2b/hSSB1 Und Und
Nprl3 Und Und
Ofd1 Joubert syndrome 10, oral-facial-digital syndrome I,  
Simpson-Golabi-Behmel syndrome, type 2
CL/P
Osr2 Und CL/P
Pak1ip1 Und Und
Pax9 Tooth agenesis, selective, 3 Und
Pbx1 Leukemia, acute pre-B-cell Und
Pdgfc Und CL/P
Pdgfra Gastrointestinal stromal tumor, somatic CL/P
Pds5a Und Und
Pdss2 Coenzyme Q10 deficiency, primary, 3 Und
Phc1/Rae28 Und Und
Piga Multiple congenital anomalies-hypotonia-seizures  
syndrome 2; paroxysmal nocturnal hemoglobinuria, somatic
Und
Pitx1 Clubfoot, congenital, with or without deficiency  
of long bones and/or mirror-image polydactyly,  
Liebenberg syndrome
CL/P
Pitx2 Axenfeld-Rieger syndrome, type 1;  
iridogoniodysgenesis, type 2; Peters anomaly
Und
Pkdcc/Vlk Und Und
Pnn Und Und
Prdm16 Cardiomyopathy, dilated, 1LL; left ventricular  
noncompaction 8
Prickle1 Epilepsy, progressive myoclonic Und
Prrx1/Prx1/Mhox Agnathia-otocephaly complex CL/P
Ptch1/Ptc1 Basal cell nevus syndrome (Gorlin syndrome) CL/P
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Gene Syndromic/non-syndromic Orofacial phenotype
Pygo2 Und Und
Rad23b Und Und
Rax Microphthalmia, isolated 3 Und
Recql4 Baller-Gerold syndrome, RAPADILINO  
syndrome, Rothmund-Thomson syndrome
CL/P
Ror2 Robinow syndrome,  
autosomal recessive
CL/P
Rspo2 Und Und
Runx2 Cleidocranial dysplasia CL/P
Ryk Und Und
Ryr1 Central core disease, King-Denborough syndrome,  
minicore myopathy with external ophthalmoplegia
Und
Sall3 Und Und
Satb2 Glass syndrome CL/P
Sc5d/Sc5dl Und Und
Schip1 Und Und
Sdccag8 Bardet-Biedl syndrome 16, Senior-Loken  
syndrome 7
Und
Serpinh/Hsp47 Osteogenesis imperfecta, type X Und
Shh Holoprosencephaly-3 CL/P
Shox2 Und Und
Sim2 Und Und
Slc32a1/Viaat Und Und
Smad4 Juvenile polyposis/hereditary hemorrhagic  
telangiectasia syndrome
Und
Smad7 Und Und
Smo/Smoh Basal cell carcinoma, somatic Und
Smoc Microphthalmia with limb abnormalities CL/P
Snai2 Piebaldism Und
Sox11 Mental retardation, autosomal dominant, 27 Und
Sox5 Und Und
Sox9 Acampomelic campomelic dysplasia CL/P
Sp8 Und Und
Spry1 Und Und
Spry2 Und Und
Sumo1 Orofacial cleft 10 CL/P
Tbx1 DiGeorge syndrome CL/P
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Upon cross-referencing the KO mice available through the Jackson Laboratory (http://www.
informatics.jax.org/diseasePortal) and performing a literature search on PubMed, Web of 
Science, and similar scholarly databases, we can provide an accurate account of all cur-
rently available mouse models with phenotypes concurrent with our understanding of CL/P. 
Furthermore, physicians and researchers alike are searching for a coalescence of treatment 
strategies, including gene therapy, to replace our current therapeutic approaches that consist 
mainly of a lifetime persistence of surgeries with less than consistent results due, in part, to 
non-standardization of procedures. What follows is an in-depth look, in order of current domi-
nance in the landscape of research, at the mouse models currently being used to study the 
etiologic determinants of orofacial clefting.
Gene Syndromic/non-syndromic Orofacial phenotype
Tbx2 Und Und
Tbx22 Cleft palate with ankyloglossia CL/P
Tcof1 Treacher-Collins syndrome CL/P
Tctn2 Meckel syndrome 8 CL/P
Tgfb2 Loeys-Dietz syndrome, type 4 CL/P
Tgfb3 Arrhythmogenic right ventricular dysplasia 1 CL/P
Tgfbr1/Alk5 Loeys-Dietz syndrome, type 1 CL/P
Tgfbr2 Loeys-Dietz syndrome, type 2 CL/P
Trp63/Tp63 Ectrodactyly, ectodermal dysplasia, and cleft lip/palate  
syndrome 3; orofacial cleft 8, Hay-Wells syndrome, limb-
mammary syndrome
CL/P
Tshz1 Aural atresia, congenital Und
Ugdh Und Und
Vax1 Microphthalmia, syndromic 11 CL/P
Vegfa Und Und
Wdpcp Und Und
Whsc1 Und Und
Wls/Gpr177 Und Und
Wnt5a Robinow syndrome,  
autosomal dominant
CL/P
Wnt9b Und Und
Zeb1 Corneal dystrophy Und
Zic3 Congenital heart defects, non-syndromic;  
heterotaxy, visceral, 1; VACTERL association
CL/P
Zpf640/Mzf6d Und Und
Genes highlighted here are specifically mentioned in the pathways discussed in this chapter and listed separately in 
Tables 2–7. Phenotypes included are derived from the Online Mendelian Inheritance in Man (OMIM).
Table 1. Summary of genes with known involvement in the etiology of orofacial abnormalities in mice.
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2.1. TGF beta (TGFβ) signaling pathway
A number of genes from the TGF beta (TGFβ) signaling pathway that play a role in palato-
genesis in mice are many (Table 2). Members of this “superfamily” play an important role 
in the development of Meckel’s cartilage and the mandible— thus, alteration or inactivation 
of particular members can lead to cleft palate [2]. TGFβ receptors are dimeric and consist of 
two types—type I and type II—of receptors with serine/threonine kinase activation. Once 
activated, these receptors function in such a way that SMAD transcription factors are phos-
phorylated, and through a cascade, eventually these SMADs make it into the nucleus where 
they function to modulate the transcription of particular subsets of genes [3]. The SMADs 
can either activate or repress the gene to which they bind. As such, a combination of dimeric 
receptors and ligands can result in any number of outcomes for a cell. In particular, TGFβ is 
Gene Syndromic/non-syndromic Orofacial phenotype
Acvr1/Alk2 Submucosal cleft/fibrodysplasia  
ossificans progressiva
Und
Acvr2a Und Und
Bmp4 Microphthalmia, syndromic 6 CL/P
Bmpr1a/Alk3 Juvenile polyposis syndrome, CP
Chrd Und CL
Cited2 Atrial septal defect 8, ventricular  
septal defect 2
Und
Foxc2/Mfh1 Lymphedema-distichiasis syndrome CL/P
Foxd3 Und Und
Foxe1/Titf2/Fkhl15 Bamforth-Lazarus syndrome CL/P
Foxf2 Und Und
Fst Und Und
Gdf11/Bmp11 Und Und
Inhba Und Und
Map3k7/ Tak1 Und Und
Smad4 Juvenile polyposis/hereditary  
hemorrhagic telangiectasia syndrome
Und
Smad7 Und Und
Tgfb2 Loeys-Dietz syndrome, type 4 CL/P
Tgfb3 Arrhythmogenic right ventricular  
dysplasia 1
CL/P
Tgfbr1/Alk5 Loeys-Dietz syndrome, type 1 CL/P
Tgfbr2 Loeys-Dietz syndrome, type 2 CL/P
Table 2. TGF beta/BMP signaling pathway.
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involved in several critical functions that take place during embryogenesis, including prolif-
eration, apoptosis, and cell differentiation.
Also, critical to normal development of the palate is the temporal and spatial distribution of 
the members of the TGFβ signaling pathway. The importance of this timing aspect may be 
that these structures, similar to morphogens, inducing specific tissue formation at identifiable 
time points in development [4]. This information can be used in the development of novel 
treatment strategies in humans with known gene mutations or deficiencies.
Typically, TGFβ receptor activation recruits and phosphorylates SMAD2 and SMAD3 at the 
carboxyl terminus via TGFβ receptor I. This method of signaling is generally what is meant 
by the term SMAD-dependent TGFβ signaling. However, TGFβ signaling can occur in lieu 
of SMAD activation via phosphorylation—pathways known to be activated in this manner 
include MAPK pathways (i.e., ERK, NJK, and p38) [5]. Inherently, this creates a purported 
“balance” between the levels of SMAD-dependent and SMAD-independent TGFβ signaling 
that exists through the development of normal palatogenesis. When we discuss the SMAD-
independent pathways, it has been proposed that these are the result of posttranslational 
modifications which occur to either of the two types of TGFβ receptors. These mechanisms 
and their subsequent cascades are under current investigation and not yet entirely known [5].
Distinct members of the TGFβ superfamily, utilizing a separate series of SMAD proteins 
(SMAD1/5/9), are the bone morphogenetic proteins (BMPs). There are a number of BMP 
ligands known and two distinct receptor types—type I and type II. As mentioned, there 
appears to be a temporal and spatial distribution of this family, which is critical for the func-
tion of BMPs, which are very well researched with regard to palatogenesis. In particular, Bmp4 
cKO mice show clefting of the lip, both uni- and bilaterally [6]. Understandably, BMP recep-
tors play a role in orofacial clefting as well; in addition, there is a distinct involvement in tooth 
morphogenesis for BMP receptors, notably Bmpr1a [7]. This molecule and its related receptors 
have an essentially unparalleled significance in the etiologic pathogenesis of CL/P. Bmpr1a 
cKO embryos, while also showing tooth morphology defects, die from orofacial clefting [6, 7].
2.2. Hedgehog signaling pathway
When one first thinks of SHH, it is likely that we recall the molecule’s importance in left-right 
patterning of the embryo, dorsal-ventral establishment of the neural tube, and brain develop-
ment, among other functions. Intrinsic properties of these morphogenic functions include 
signaling for cell proliferation and survival. The alteration of these properties can lead SHH 
receptors and/or ligands to function abnormally, thus, in some cases, altering the pattern-
ing of cranial neural crest cells during embryonic development. Modulation of the molecules 
involved in hedgehog signaling has been shown to present with CL/P phenotype in mice.
The full breadth of hedgehog signaling molecules with known involvement in orofacial cleft-
ing in mice spans several other pathways (Table 3). A notable characteristic of the mechanism 
of action for Shh can be observed in nasal epithelium of mice where Shh is reported absent. 
These mice develop cleft palate, while mice with overexpressed Shh are shown to express 
failure of growth of the maxillary processes and thus no fusion; this leads to cleft palate and 
several missing bones within the nasal process [8].
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Another notable molecule involved in the hedgehog signaling pathway is Ptch1, a transcriptional 
target of Shh as well, which displays a gradient mimicking that of Shh in the palatal shelves dur-
ing early palatogenesis, at E13.5 [8]. Similarly, the palatal mesenchyme adjacent to the medial-
edge epithelium (MEE) present in the nasal epithelium expressed Smo in significant amounts 
[9]. In each case with the hedgehog signaling molecules, there is expression in the palatal mes-
enchyme, with the highest level of expression for most molecules adjacent to the palatal oral 
epithelium [9]. The awareness of this spatial and temporal expression provides a niche for the 
insertion or potential innervation of gene products given therapeutically. The effects of an abnor-
mal amount of SHH signaling are palpable. Restoration of the proper balance of SHH signaling 
throughout development may play a role in treatment options in the near future, and delivery 
methods are currently underway to target particular areas of known involvement in CL/P.
2.3. Wnt signaling pathway
The Wnt signaling pathway plays another exceptional role in craniofacial morphogenesis in 
mice (Table 4). There are 19 known Wnt proteins found in humans, with combinations of differ-
ing ligands and receptors allowing for a mixture of modulatory effects from similar molecules. 
Between the receptors available, there exist three distinct pathways: the β-catenin-dependent 
(canonical), β-catenin-independent planar cell polarity (PCP), and β-catenin-independent Ca2+ 
pathways. β-Catenin is a transcription factor that, when Wnt ligands are present, will persist and 
Gene Syndromic/non-syndromic Phenotypes
Gli2 Culler-Jones syndrome, holoprosencephaly-9 CL/P
Gli3 Greig cephalopolysyndactyly CL/P
Ptch1/Ptc1 Basal cell nevus syndrome (Gorlin syndrome) CL/P
Shh Holoprosencephaly-3 CL/P
Smo/Smoh Basal cell carcinoma, somatic Und
Table 3. Hedgehog signaling pathway.
 
Gene Syndromic/non-syndromic Phenotypes
Ctnnb1 Mental retardation, autosomal dominant 19 Und
Edn1 Auriculocondylar syndrome 3 CL/P
Fzd2 Und Und
Gsk3b Und Und
Lrp6 Und Und
Prickle1 Epilepsy, progressive myoclonic Und
Wnt5a Robinow syndrome, autosomal dominant CL/P
Wnt9b Und Und
Table 4. Wnt signaling pathway.
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translocate into the nucleus; the factor is otherwise degraded [7]. The Wnt pathway is involved 
in a variety of embryogenic and developmental events, similar to the SHH pathway. In terms of 
craniofacial development, we see a critical role for the Wnt signaling pathway when we observe 
the generation, migration, proliferation, and survival of cranial neural crest cells [10].
A notable Wnt ligand involved in canonical signaling is Wnt9b. Expressed between the facial 
processes, alterations in signaling of this molecule have shown to express clefting in mice. 
Additionally, Wnt9b null mice have a distinctly shorter nasal process and shortened maxillary 
processes, a direct link to bilateral CLP [11]. This expression is apparent with FGF molecules, 
one of the many molecules involved with and expressively determined by Wnt signaling. A 
deletion of either the epithelium in which Wnt9b is found or a KO of the ligand (gene product) 
itself results in a similar cleft lip phenotype [11].
While the plethora of numerous other Wnt signaling targets and mediators exist, a receptor of 
particular interest and importance currently is Lrp6. This receptor functions in the canonical 
Wnt pathway as well and contains members of the Frizzled family as well as a co-receptor, 
which can be low-density lipoprotein receptor-related protein 6 (LRP6). Research has shown 
that Lrp6 null mice demonstrate bilateral clefting of the lip as well and cleft palate and mid-
line clefting of the mandible [12]. These mice also express defects in the neural tube, eye, and 
brain among others. The orofacial clefting defects were observed at E13.5 in these Lrp6 null 
mice, with full penetrance of CLP and mandibular defects [12]. Again, we see a pattern that 
current research has established wherein a spatial and temporal time table has been created. 
This knowledge, as it continues to expand with further genomic testing and mouse model 
availability, should prove highly useful in the development of novel therapies.
2.4. FGF signaling pathway
While it has already been briefly discussed, one can see that the FGF signaling pathway also 
expands across several currently known molecular cascades. In humans and in mice, muta-
tions resulting in dysfunction of the FGF signaling pathway are known to result in a variety 
of craniofacial abnormalities and syndromes—one proponent of which is orofacial clefting. 
An important role of FGF signaling is seen in the induction of the neural crest while being 
widely expressed in epithelial-mesenchymal interactions elsewhere. Particularly in the facial 
primordia, FGF signaling is absolutely critical in the proper development and formation of 
the palate as it is present in both endochondral (i.e., Meckel’s cartilage) and intramembranous 
bones [13]. When we consider palatogenesis, FGF molecules have been shown to be involved 
in multiple stages—from palatal shelf elevation to fusion of MEE. KO mice have played a 
key role in our understanding of the function of various FGFs and their relation to orofacial 
clefting.
There are 23 distinct FGF ligands known and four receptors to which they bind. Alternative 
splicing generates several receptor variants which allows for multiple binding combinations 
and, thus, different functionalities temporally during embryogenesis. Various receptors are 
located in the epithelium and mesenchyme throughout the embryo, and research has eluci-
dated many roles that these molecules play; for our interest, much emphasis has been placed 
on suture fusion (craniosynostosis) and palatogenesis.
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Mutations in FGF receptors have been shown to present with a variety of midfacial syndromes 
in mice as well (Table 5). For example, in humans, gain-of-function mutations in FGFR2 and 
FGFR3 have been consistently observed in individuals with Crouzon syndrome—a genetic dis-
order that includes craniosynostosis in its list of defects associated with the syndrome. More 
relevant here, however, is that a KO mouse model in which the Fgfr1 receptors are missing in 
the cranial neural crest (CNC) cells directly results in CLP due to failures in the proliferation and 
migration of said cells [14]. Likewise, research has shown that ectopic activation of Fgf8 results in 
increased proliferation and a failure of the palatal shelves to elevate properly [15]. This is excep-
tionally interesting in that it is a rare case in which an increase in cell proliferative activity has 
resulted in CP; in many cases, CP is the result of an obvious decrease in the amount of cell pro-
liferation. In the case of Fgf8 activation, the palatal shelves were still unable to elevate in a normal 
manner, and thus the palatal morphology was altered, and a CP phenotype was observed.
The FGF signaling pathway has been, and is currently being, extensively studied. Spatial 
expression of the molecules involved in the pathway has been seen widely throughout 
the developing mouse embryo, while the temporal expression continues to be expounded 
upon. Investigations are ongoing to further our knowledge of why characteristically oppos-
ing molecular processes (i.e., reduction versus activation of cellular proliferation) may result 
in the same phenotype. In all, what remains important is that future treatment options are 
expanding all the time. The more we learn about all the plethora of molecular signals that 
interact during embryogenesis—which is similar enough between mouse and human—the 
more physicians and surgeons are able to generate new and better therapies.
2.5. MAPK signaling pathway
The mitogen-activated protein kinase (MAPK) signaling pathway—also known as the ERK 
pathway—plays a role in craniofacial development of mice as early as E10.5 [16]. MAPK is 
a protein kinase that functions in conjunction with two others, MAPKKK (e.g., RAF) and 
MAPKK (e.g., MEK1/2). Upon activation, these effector molecules can act in either the cytosol 
or the nucleus. Growth factors, including TGFβ, BMPs, and fibroblast growth factor (FGF), 
Gene Syndromic/non-syndromic Phenotypes
Fgf10 Aplasia of lachrymal and salivary glands Und
Fgf18 Und Und
Fgf9 Und Und
Fgfr1 Non-syndromic cleft lip/palate, Hartsfield syndrome,  
hypogonadotropic hypogonadism 2, Pfeiffer syndrome
CL/P
Fgfr2 Apert syndrome CL/P
Gbr2 Und Und
Spry1 Und Und
Spry2 Und Und
Table 5. FGF signaling pathway.
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can modulate this same protein kinase cascade, and each of the molecules listed is also known 
to be involved with development of the palate [17]. Additionally, analysis of the potential 
spatial representation of active (phosphorylated) ERK1/ERK2 in the palate has resulted in the 
discovery this pathway persists in both the epithelium and the mesenchyme associated with 
the developing palatal shelves [17].
Immunohistochemistry using an antibody against an activated form of ERK has shown ERK 
signaling in the frontonasal process, brachial arches, and extraembryonic ectoderm, among 
other craniofacial-associated regions [16]. Research has also shown associations between MAPK 
signaling and growth factor pathway genes that include Fgf9/10/18, Alk5, and Itgb1 among oth-
ers and vary craniofacial clefting and defects in mice, including mandibular osteogenic and 
tongue abnormalities [17]. The inclusion of the mandible and tongue is important in that it adds 
to the overall complexity of the defect, thus making treatment options that much more of a pri-
ority. Current investigations are ongoing to pinpoint time points and the distribution of MAPK 
 signaling and its numerous molecular effectors during embryogenesis in mice (Table 6).
2.6. Homeobox proteins
Homeobox proteins and their respective KO/mutant mouse models are used to represent eas-
ily observable phenotypes. Some of the most well-studied homeobox genes in mice include 
Msx1/2, Pax9, and Alx1 [1]. The reason for their grouping and relatively well-known actions 
has to do with the fact that transcription factors encoded by homeobox genes act in a site-
specific manner [18]. These gene products exist, segmentally, throughout the body and are 
palpable during nearly all stages of development. As such, we know that there are Hox hom-
eogenes which control bone patterning in the limb buds; similarly, there are separate homeo-
genes that are associated with craniofacial development in mice (Table 7).
Specifically, research has shown that a human MSX1 missense mutation can lead to orofacial 
clefting as well as selective tooth agenesis [19]. Mutations in this gene, as seen in other hom-
eogenes, can lead to dysfunctional protein products that act via transcriptional repression. In 
the case of Msx1, the homeodomain interacts directly with the TATA-binding protein (TBP) 
and acts directly at the start of transcription by repressing the gene completely to which it 
translocates. In some scenarios, heterodimers will form between homeodomain proteins, and 
a balance must persist in which they are co-regulatory.
Gene Syndromic/non-syndromic Phenotypes
Chuk/Ikk1/Tcf16 Cocoon syndrome Und
Egfr Und Und
Grb2 Und Und
Pdgfra Gastrointestinal stromal tumor, somatic CL/P
Crk Und Und
Itgb1 Und Und
Table 6. MAPK signaling pathway.
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As a result of these proteins acting within their respective zones (or “sites”), one can assume 
that there is an overlap with the adjacent homeodomain. Such overlap is observed between 
Msx1 and Msx2 throughout the craniofacial structures during development—including the 
skull, suture mesenchyme, and teeth [20]. Inherent in their molecular categorization is the 
idea that we know where, and upon which tissues, these proteins interact. There are a num-
ber of homeogenes involved in craniofacial development that modulate palatogenesis and 
patterning, among a variety of other roles. Due to their known functions during embryogen-
esis, further research is ongoing regarding the effect of varying homeogene mutations on cell 
proliferation, survival, and adhesion. The culmination of knowledge that lies within these 
determinants of normal development will indubitably result in opportunities for the future 
application of therapeutic modalities.
Gene Syndromic/non-syndromic Phenotypes
Alx1 Frontonasal dysplasia 3 CL/P
Alx3 Frontonasal dysplasia 1 CL/P
Alx4 Frontonasal dysplasia 2, parietal foramina 2,  
craniosynostosis 5
Cleft alae nasi
Barx1 Und Und
Dlx1 Und Und
Dlx2 Und Und
Dlx5 Split-hand/foot malformation 1 with  
sensorineural hearing loss
CL/P
Gbx2 Und Und
Gsc Short stature, auditory canal atresia, mandibular  
hypoplasia, skeletal abnormalities
Und
Hoxa2 Microtia with or without hearing impairment Und
Msx1 Ectodermal dysplasia 3, Witkop-type orofacial cleft 5 CL/P
Msx2 Craniosynostosis, type 2; parietal foramina 1, parietal  
foramina with cleidocranial dysplasia
CL/P
Pax9 Tooth agenesis, selective, 3 Und
Pitx1 Clubfoot, congenital, with or without deficiency of long bones  
and/or mirror-image polydactyly, Liebenberg syndrome
CL/P
Pitx2 Axenfeld-Rieger syndrome, type 1; iridogoniodysgenesis,  
type 2; Peters anomaly
Und
Prrx1/Prx1/Mhox Agnathia-otocephaly complex CL/P
Rax Microphthalmia, isolated 3 Und
Shox2 Und Und
Vax1 Microphthalmia, syndromic 11 CL/P
Table 7. Homeobox protein signaling pathway.
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2.7. Remaining mouse strains exhibiting CL/P phenotype
Here, we have put into one table a list of the genes with a known association, whether syn-
dromic or non-syndromic, to the development of the palate in mouse (Table 1). It should be 
noted that not all genes in this table have shown their identical, cross species phenotype in 
humans.
2.8. The future of CL/P therapy
A bonafide surgical protocol remains to be standardized for the repair of CL/P. Fortunately, 
ongoing research concerning therapeutic interventions for this relatively common birth defect 
has recently begun to delve into new and improved options for repair with, hopefully, more 
consistent and stable results for patients. The current “golden standard” treatment option for 
pediatric oral surgeons involves bone grafting, or alveoloplasty, usually from autogenous 
sites—but this has many complications associated with both the grafting procedure and the 
agreed-upon effectiveness in reconstructing the palate over time [21]. Postoperative follow-
up has shown success rates ranging from 41 to 73%, which is far from standardized, while 
there also exists the possibility (in 11–23% of patients) of oronasal fistulas, which come with 
their own brand new set of complications for the patient [22]. In short, the most effective inter-
ventions in use today are far from ideal for the patent and result in long-term risk of complica-
tions from grafting procedures, disturbance of adjacent craniofacial development, and, over 
time, a significant financial encumbrance on the patient. Techniques including gene delivery, 
in vitro engineered tissue transplantation, and regenerative medicine are being probed for 
efficacy, and some are showing promising results thus far.
An exceptionally exciting modality is the use of stem cells. One method of delivering these 
cells is via a biocompatible scaffold upon which cells that have been previously harvested 
were cultured and attached. Materials including collagen, hyaluronic acid, and hydroxyapa-
tite have been utilized in attempts to develop such scaffolds [23–25]. These scaffolds have 
been engineered as injectable gels, mesh networks, and foams. Ideally, this aids in the pro-
cedure being as minimally invasive as possible while also providing maximum benefit and 
adequate delivery to the area of interest. This therapy can be modified to include signaling 
molecules and other types of differentiated cells—which preferably have a known clinical 
outcome and avoid the possibility of rejection and/or disunity with the surrounding host 
cells—and injected in a similar fashion or applied to previously engineered palates. Currently, 
autogenous mesenchymal stem cells (MSCs) are regarded as the optimum choice for in vivo 
osteogenic reconstructions; these can come from umbilical cord blood, Wharton’s jelly, and 
even the patient’s own bone marrow [26]. Tissue regenerative-specific repair of CL/P has been 
demonstrated with some success, and some are now advocating for in depth considering of 
its potential to replace traditional autogenous grafting procedures [27].
Regarding clinical studies in progress, one group has shown that in vitro differentiated MSCs 
derived from bone marrow were delivered with platelet-derived growth factor and signifi-
cant improvement was observed 3 months post-op [28]. Similarly, recombination therapies 
are being used to induce osteoblastic differentiation with BMPs formed from stem cells, 
and resulting immunohistological analysis of the bone that formed has shown normal, vital 
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 structure [29]. Finally, platelet-rich plasma (PRP) is being studied with regard to its potential 
for tissue repair in vivo. A wide variety of growth factors are present in a platelet-rich solution 
and have been shown to promote angiogenesis and extracellular matrix formation [30]. This 
intervention has some positive results—it has been shown that PRP can enhance bone regen-
eration and thus may be a useful alternative to traditional procedures for CL/P patients [31].
A number of prospective therapeutic interventions are currently being investigated, many 
with exciting outcomes thus far. CL/P etiology is not yet completely understood and is 
extremely complex. In order to properly apply this research to the human subjects, we must 
further our research to bridge the gap between an understanding of the signaling pathways, 
the rescue of the animal phenotype, and the translation of this knowledge into human treat-
ment. As research continues on the pathways mentioned in this chapter, further clinical trials 
should become available, and treatment outcomes for patients can rapidly and significantly 
improve. Moving forward, more work is needed to establish a new standard of care and a 
protocol for various differing types of orofacial clefts, but progress has proceeded rapidly in 
recent years, and the outlook is bright for the future of care for CL/P patients.
In summary, it remains within animal research where the next steps in the elucidation of 
potential treatments for CL/P must be made. Understanding the biological, molecular signal-
ing pathways and identifying a broad cause for the clefting phenotype are only the first steps 
in understanding how to treat it. Now, we need to look toward a greater understanding of the 
critical downstream events that occur as a result of the KO or cKO models being used; what 
types of tissue-tissue interactions are changing? What is the scope of the molecular activity 
being altered as a result of changing the capabilities of one gene? Once more of these ques-
tions are answered in animal models, the translation of lab research to the rescue of human 
phenotypes will become more clear. Until then, it is crucial to continue to identify all that we 
can in order to bridge the gap between KO/cKO mice, the expansive etiology surrounding 
their conditions, and the rescue of their control phenotypes.
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